AnaptysBio reported a net loss of $39.3 million for Q1 2025, an improvement from the $43.9 million loss in Q1 2024. The company saw a significant increase in collaboration revenue, reaching $27.8 million, primarily driven by royalties from Jemperli sales and a license agreement with Vanda Pharmaceuticals. Cash and investments decreased to $383.0 million, but the company reiterated its cash runway through year-end 2027.

AnaptysBio announced positive Phase 2b data for rosnilimab in rheumatoid arthritis, showing impressive safety, tolerability, and efficacy. The company reported a net loss of $21.8 million for Q4 2024, with collaboration revenue of $43.1 million. Cash and investments stood at $420.8 million at year-end 2024, with a reiterated cash runway through year-end 2027.

AnaptysBio reported a net loss of $32.9 million for the third quarter of 2024, with collaboration revenue of $30.0 million. The company's cash and investments totaled $458.0 million, reiterating cash runway through year-end 2026. Clinical trial milestones for ANB032 and rosnilimab are anticipated in December 2024 and February 2025, respectively.